Neuralstem Company Profile (NASDAQ:CUR)

About Neuralstem (NASDAQ:CUR)

Neuralstem logoNeuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CUR
  • CUSIP: N/A
  • Web: www.neuralstem.com
Capitalization:
  • Market Cap: $20.82 million
  • Outstanding Shares: 11,899,000
Average Prices:
  • 50 Day Moving Avg: $5.26
  • 200 Day Moving Avg: $4.64
  • 52 Week Range: $1.73 - $6.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.78
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16,246.00
  • Price / Sales: 1,281.75
  • Book Value: $0.83 per share
  • Price / Book: 2.11
Profitability:
  • EBIDTA: ($18,210,000.00)
  • Net Margins: -191,652.16%
  • Return on Equity: -425.79%
  • Return on Assets: -122.42%
Debt:
  • Current Ratio: 3.41%
  • Quick Ratio: 3.41%
Misc:
  • Average Volume: 172,168 shs.
  • Beta: 2.08
  • Short Ratio: 9.82
 
Frequently Asked Questions for Neuralstem (NASDAQ:CUR)

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.02. Neuralstem had a negative return on equity of 425.79% and a negative net margin of 191,652.16%. View Neuralstem's Earnings History.

Where is Neuralstem's stock going? Where will Neuralstem's stock price be in 2017?

3 brokers have issued 1 year price targets for Neuralstem's shares. Their forecasts range from $1.20 to $4.00. On average, they anticipate Neuralstem's share price to reach $2.79 in the next twelve months. View Analyst Ratings for Neuralstem.

Who are some of Neuralstem's key competitors?

Who are Neuralstem's key executives?

Neuralstem's management team includes the folowing people:

  • Richard J. Daly, Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer
  • Scott V. Ogilvie, Independent Director
  • William C. Oldaker, Independent Director
  • Sandford D. Smith, Independent Director
  • Stanley I. Westreich, Independent Director

How do I buy Neuralstem stock?

Shares of Neuralstem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuralstem's stock price today?

One share of Neuralstem stock can currently be purchased for approximately $1.75.


MarketBeat Community Rating for Neuralstem (NASDAQ CUR)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neuralstem (NASDAQ:CUR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.79 (59.62% upside)

Analysts' Ratings History for Neuralstem (NASDAQ:CUR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/16/2017S&P Equity ResearchLower Price Target$3.69 -> $3.18N/AView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$1.20N/AView Rating Details
11/7/2016AegisInitiated CoverageBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$4.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Neuralstem (NASDAQ:CUR)
Earnings by Quarter for Neuralstem (NASDAQ:CUR)
Earnings History by Quarter for Neuralstem (NASDAQ CUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016Q3($0.03)($0.05)ViewN/AView Earnings Details
8/11/2016Q2($0.05)($0.04)$2.50 million$2.50 millionViewN/AView Earnings Details
5/9/2016Q1($0.06)($0.07)ViewN/AView Earnings Details
3/14/2016Q4($0.07)($0.05)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q2($0.06)($0.06)ViewN/AView Earnings Details
5/8/2015Q115($0.07)($0.06)$2.92 millionViewN/AView Earnings Details
4/20/2015($0.07)($0.06)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.05)($0.06)$0.01 millionViewN/AView Earnings Details
11/7/2014Q314($0.05)($0.05)$0.01 millionViewN/AView Earnings Details
8/8/2014Q214($0.05)($0.08)$0.10 million$0.01 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.04)$0.35 million$0.00 millionViewN/AView Earnings Details
3/10/2014Q4 2013($0.06)($0.04)ViewN/AView Earnings Details
11/11/2013Q3($0.04)($0.09)ViewN/AView Earnings Details
8/9/2013Q213($0.05)($0.09)$0.08 million$0.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.04)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neuralstem (NASDAQ:CUR)
Current Year EPS Consensus Estimate: $-2.26 EPS
Next Year EPS Consensus Estimate: $-2.24 EPS

Dividends

Dividend History for Neuralstem (NASDAQ:CUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neuralstem (NASDAQ:CUR)
Insider Ownership Percentage: 19.25%
Institutional Ownership Percentage: 12.46%
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Institutional Ownership by Quarter for Neuralstem (NASDAQ:CUR)
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Richard J DalyCEOBuy7,500$4.00$30,000.00View SEC Filing  
3/24/2017Jones Jonathan Brian LloydCFOBuy5,455$5.50$30,002.50View SEC Filing  
2/24/2017Richard J DalyCEOBuy2,591$3.86$10,001.26View SEC Filing  
1/25/2017Richard J DalyCEOBuy2,841$3.52$10,000.32View SEC Filing  
12/23/2016Richard J DalyCEOBuy32,259$0.31$10,000.29View SEC Filing  
11/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
10/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
9/23/2016Richard J DalyCEOBuy31,250$0.32$10,000.00View SEC Filing  
11/16/2015Karl JoheInsiderSell25,000$1.09$27,250.00View SEC Filing  
11/9/2015Karl JoheInsiderSell25,000$1.18$29,500.00View SEC Filing  
11/2/2015Karl JoheInsiderSell25,000$1.17$29,250.00View SEC Filing  
10/26/2015Karl JoheInsiderSell25,000$1.13$28,250.00View SEC Filing  
10/19/2015Karl JoheInsiderSell25,000$1.23$30,750.00View SEC Filing  
10/12/2015Karl JoheInsiderSell25,000$1.31$32,750.00View SEC Filing  
10/5/2015Karl JoheInsiderSell25,000$1.26$31,500.00View SEC Filing  
9/28/2015Karl JoheInsiderSell25,000$1.64$41,000.00View SEC Filing  
9/21/2015Karl JoheInsiderSell25,000$1.52$38,000.00View SEC Filing  
9/2/2014Karl JoheInsiderSell6,000$4.09$24,540.00View SEC Filing  
8/1/2014Karl JoheInsiderSell6,000$2.78$16,680.00View SEC Filing  
7/1/2014Karl JoheInsiderSell6,000$4.17$25,020.00View SEC Filing  
6/2/2014Karl JoheInsiderSell6,000$4.25$25,500.00View SEC Filing  
5/5/2014William Clyde OldakerDirectorBuy15,235$3.50$53,322.50View SEC Filing  
4/22/2014Richard GarrCEOSell7,000$4.25$29,750.00View SEC Filing  
4/1/2014Karl JoheInsiderSell6,000$4.11$24,660.00View SEC Filing  
3/20/2014Karl JoheInsiderSell6,000$4.04$24,240.00View SEC Filing  
10/18/2013Karl JoheInsiderSell10,000$2.44$24,400.00View SEC Filing  
9/20/2013Karl JoheInsiderSell10,000$2.62$26,200.00View SEC Filing  
9/19/2013Karl JoheInsiderSell10,000$2.61$26,100.00View SEC Filing  
8/20/2013Karl JoheInsiderSell20,000$1.55$31,000.00View SEC Filing  
7/22/2013Karl JoheInsiderSell12,800$1.62$20,736.00View SEC Filing  
6/20/2013Karl JoheInsiderSell12,800$1.40$17,920.00View SEC Filing  
6/7/2013Richard GarrCEOSell6,000$1.42$8,520.00View SEC Filing  
5/20/2013Karl JoheInsiderSell12,800$1.51$19,328.00View SEC Filing  
2/25/2013Richard GarrCEOSell12,000$1.15$13,800.00View SEC Filing  
11/20/2012Karl JoheInsiderSell12,800$1.00$12,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neuralstem (NASDAQ:CUR)
Latest Headlines for Neuralstem (NASDAQ:CUR)
Source:
DateHeadline
nasdaq.com logoMid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares Plunge
www.nasdaq.com - July 27 at 5:59 PM
finance.yahoo.com logoNeuralstem Announces Pricing of Public Offering of Common Stock and Warrants
finance.yahoo.com - July 27 at 5:59 PM
nasdaq.com logoNeuralstem: NSI-189 Phase 2 Trial Fails To Meet Primary Efficacy Endpoint
www.nasdaq.com - July 27 at 2:20 AM
streetinsider.com logoAfter-Hours Movers 07/26: (AXTI) (NTGR) (FB) Higher; (CUR) (CYH) (BWLD) Lower (more...)
www.streetinsider.com - July 27 at 2:20 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma
finance.yahoo.com - July 26 at 6:13 PM
finance.yahoo.com logoNeuralstem Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - July 26 at 6:13 PM
rttnews.com logoPositive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX
www.rttnews.com - July 26 at 3:43 AM
benzinga.com logoMid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss - Benzinga
www.benzinga.com - July 25 at 10:39 PM
marketwatch.com logoUPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss - MarketWatch
www.marketwatch.com - July 25 at 10:39 PM
finance.yahoo.com logoNeuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder
finance.yahoo.com - July 25 at 5:37 PM
finance.yahoo.com logoUPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss
finance.yahoo.com - July 25 at 5:37 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : July 4, 2017
finance.yahoo.com - July 5 at 12:22 AM
finance.yahoo.com logoNeuralstem Added to the Russell Microcap® Index
finance.yahoo.com - June 26 at 5:23 PM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 9 at 3:58 PM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Sees Large Decline in Short Interest
www.americanbankingnews.com - June 3 at 2:20 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 6:04 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 4:22 PM
americanbankingnews.com logoRichard J. Daly Buys 7,500 Shares of Neuralstem, Inc. (CUR) Stock
www.americanbankingnews.com - May 18 at 1:32 PM
streetinsider.com logoNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder
www.streetinsider.com - May 17 at 9:42 PM
streetinsider.com logoNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder - StreetInsider.com
www.streetinsider.com - May 17 at 4:41 PM
finance.yahoo.com logoNeuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
finance.yahoo.com - May 17 at 4:41 PM
finance.yahoo.com logoNeuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:08 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: MannKind and Neuralstem
finance.yahoo.com - May 11 at 5:14 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:14 PM
finanznachrichten.de logoGainers & Losers Of May 10: CUR, TEAR, PRTO, CXRX, DERM...
www.finanznachrichten.de - May 11 at 2:49 AM
americanbankingnews.com logoZacks: Neuralstem, Inc. (CUR) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 10 at 8:44 PM
globenewswire.com logoNeuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
globenewswire.com - May 10 at 4:47 PM
finance.yahoo.com logoNeuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
finance.yahoo.com - May 10 at 4:47 PM
seekingalpha.com logoNeuralstem, Inc. (CUR)
seekingalpha.com - May 4 at 9:45 PM
americanbankingnews.com logoNeuralstem (CUR) Receiving Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 21 at 6:28 PM
businesswire.com logoBioAxone BioSciences Appoints Dr. Catherine Sohn to Lead Corporate Development
www.businesswire.com - April 20 at 4:45 PM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 4:34 PM
americanbankingnews.com logoNeuralstem (CUR) Getting Somewhat Negative Media Coverage, Report Finds
www.americanbankingnews.com - April 13 at 12:54 PM
streetinsider.com logoNeuralstem (CUR) Adds Four Cohorts to Ongoing Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury - StreetInsider.com
www.streetinsider.com - April 13 at 11:48 AM
finance.yahoo.com logoNeuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury
finance.yahoo.com - April 12 at 11:22 AM
finance.yahoo.com logoETFs with exposure to Neuralstem, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:16 AM
americanbankingnews.com logoJones Jonathan Brian Lloyd Acquires 5,455 Shares of Neuralstem, Inc. (CUR) Stock
www.americanbankingnews.com - March 27 at 11:05 PM
biz.yahoo.com logoNEURALSTEM, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 23 at 5:09 PM
us.rd.yahoo.com logoNeuralstem Reports Year End 2016 Fiscal Results and Business Update
us.rd.yahoo.com - March 23 at 5:09 PM
streetinsider.com logoNeuralstem (CUR) Reports Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury - StreetInsider.com
www.streetinsider.com - March 11 at 10:09 AM
americanbankingnews.com logoNeuralstem, Inc. (CUR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 11 at 12:43 AM
us.rd.yahoo.com logoToday's Research Reports on Market Movers: Neuralstem and Real Goods Solar
us.rd.yahoo.com - March 10 at 5:39 PM
us.rd.yahoo.com logoNeuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury
us.rd.yahoo.com - March 9 at 5:11 PM
globenewswire.com logoNeuralstem to Present at 29th Annual ROTH Conference - GlobeNewswire (press release)
www.globenewswire.com - March 8 at 10:20 PM
streetinsider.com logoNeuralstem (CUR) Announces Publication of NSI-189 Preclinical Data
www.streetinsider.com - March 1 at 1:18 PM
streetinsider.com logoNeuralstem (CUR) Announces Publication of NSI-189 Preclinical Data - StreetInsider.com
www.streetinsider.com - February 28 at 4:48 PM
us.rd.yahoo.com logoNeuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology
us.rd.yahoo.com - February 28 at 10:33 AM
biz.yahoo.com logoNEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 27 at 5:47 PM
us.rd.yahoo.com logoNeuralstem Announces Issuance of U.S. Patent Covering NSI-189
us.rd.yahoo.com - February 22 at 4:49 PM
us.rd.yahoo.com logo7:04 am Neuralstem confirms that U.S. Patent No. 9572807 was issued by the United States Patent and Trademark Office for NSI-189 the lead compound in Neuralstem's neurogenic small molecule program in development for the treatment of major d
us.rd.yahoo.com - February 22 at 4:49 PM

Social

Chart

Neuralstem (CUR) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff